123 related articles for article (PubMed ID: 393384)
1. DTIC and combination therapy for melanoma. II. Escalating schedules of DTIC with BCNU, CCNU, and vincristine.
Hill GJ; Metter GE; Krementz ET; Fletcher WS; Golomb FM; Ramirez G; Grage TB; Moss SE
Cancer Treat Rep; 1979; 63(11-12):1989-92. PubMed ID: 393384
[No Abstract] [Full Text] [Related]
2. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
[TBL] [Abstract][Full Text] [Related]
3. cis-Dichlorodiammineplatinum(II) and DTIC in malignant melanoma.
Karakousis CP; Getaz EP; Bjornsson S; Henderson ES; Irequi M; Martinez L; Ospina J; Cavins J; Preisler H; Holyoke E; Holtermann O
Cancer Treat Rep; 1979; 63(11-12):2009-10. PubMed ID: 393386
[TBL] [Abstract][Full Text] [Related]
4. DTIC (NSC-45388) studies in the southwest oncology group.
Costanzi JJ
Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
[TBL] [Abstract][Full Text] [Related]
5. DTIC (NSC-45388) in malignant melanoma: a perspective.
Comis RL
Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
[No Abstract] [Full Text] [Related]
6. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
7. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
Johnson RO; Metter G; Wilson W; Hill G; Krementz E
Cancer Treat Rep; 1976 Feb; 60(2):183-7. PubMed ID: 769971
[TBL] [Abstract][Full Text] [Related]
8. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Van Dyk JJ; Falkson G
Med Pediatr Oncol; 1975; 1(2):107-11. PubMed ID: 1228411
[TBL] [Abstract][Full Text] [Related]
9. Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma.
Green MR; Dillman RO; Horton C
Cancer Treat Rep; 1980 Jan; 64(1):139-42. PubMed ID: 7379047
[TBL] [Abstract][Full Text] [Related]
10. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
11. Use of combination chemotherapy with CCNU, bleomycin, and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy.
Everall JD; Dowd PM
Cancer Treat Rep; 1979 Jan; 63(1):151-5. PubMed ID: 84710
[No Abstract] [Full Text] [Related]
12. [Chemotherapy of malignant melanoma. Results of a controlled clinical trial comparing vincristine + dacarbazin (DTIC) with and without duborimycin (author's transl)].
Chauvergne J; Clavel B; Klein T; Pommatau E
Bull Cancer; 1978; 65(2):107-9. PubMed ID: 359067
[TBL] [Abstract][Full Text] [Related]
13. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma.
Seigler HF; Lucas VS; Pickett NJ; Huang AT
Cancer; 1980 Dec; 46(11):2346-8. PubMed ID: 6159960
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
15. [Combination chemotherapy of disseminated skin melanoma with nitrosomethylurea].
Perevodchikova NJ; Moros LW; Kogonia LM
Arch Geschwulstforsch; 1986; 56(4):273-81. PubMed ID: 3530176
[TBL] [Abstract][Full Text] [Related]
16. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
Bellett RE; Mastrangelo MJ; Laucius JF; Bodurtha AJ
Cancer Treat Rep; 1976 May; 60(5):595-600. PubMed ID: 791478
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.
Beretta G; Bonadonna G; Bajetta E; Tancini G; De Lena M; Azzarelli A; Veronesi U
Cancer Treat Rep; 1976 Feb; 60(2):205-11. PubMed ID: 769975
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)].
Kleeberg UR; Schreml W
Dtsch Med Wochenschr; 1976 Jun; 101(23):890-4. PubMed ID: 1269431
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Propper DJ; Braybrooke JP; Levitt NC; O'Byrne K; Christodoulos K; Han C; Talbot DC; Ganesan TS; Harris AL
Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287
[TBL] [Abstract][Full Text] [Related]
20. Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma.
Creagan ET; Schutt AJ; Long HJ; Green SJ
Med Pediatr Oncol; 1986; 14(2):86-7. PubMed ID: 3713642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
